Tenon Medical, Inc. develops minimally invasive implants for sacroiliac joint disorders with a focus on the U.S. market. Following FDA clearance in 2018 and a national launch of its Catamaran system in 2022, the company expanded its portfolio through the 2025 acquisition of the SImmetry + system. Revenue grew over 20% in fiscal 2025 to $3.94 million, yet the company continues to report significant operating losses driven by commercialization and R&D investments. Recent convertible note financing provides capital but adds financial constraints amid Nasdaq bid price compliance concerns and ongoing regulatory risks.